Edition:
United States

Kamada Ltd (KMDA.OQ)

KMDA.OQ on NASDAQ Stock Exchange Global Select Market

4.75USD
11:49am EDT
Change (% chg)

$0.15 (+3.26%)
Prev Close
$4.60
Open
$4.50
Day's High
$4.75
Day's Low
$4.50
Volume
19,830
Avg. Vol
7,794
52-wk High
$8.55
52-wk Low
$3.75

Chart for

About

No overview information found for .
No analyst recommendations are available for .

Overall

No Ratios Available.

Financials

  KMDA.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -- -- --
ROI: -- 13.60 13.19
ROE: -- 15.26 15.00

BRIEF-Kamada Gets Feedback From FDA On Proposed Phase 3 Protocol For Inhaled Alpha-1-Antitrypsin

* KAMADA RECEIVED FEEDBACK FROM FDA ON PROPOSED PHASE 3 PROTOCOL FOR INHALED ALPHA-1-ANTITRYPSIN FOR TREATMENT OF ALPHA-1 ANTITRYPSIN DEFICIENCY DISEASE

7:50am EDT

BRIEF-Kamada Ltd Q4 Earnings Per Share $0.16

* KAMADA REPORTS FINANCIAL RESULTS FOR FOURTH QUARTER AND FULL-YEAR 2017

Feb 07 2018

BRIEF-Kamada Announces Data From Phase 2 Clinical Trial Of Intravenous Alpha-1 Antitrypsin Treatment For Prevention Of Lung Transplant Rejection

* KAMADA ANNOUNCES INTERIM RESULTS FROM PHASE 2 CLINICAL TRIAL OF INTRAVENOUS ALPHA-1 ANTITRYPSIN TREATMENT FOR PREVENTION OF LUNG TRANSPLANT REJECTION

Jan 08 2018

BRIEF-Kamada Announces Collaboration With Hospitals To Evaluate Its Product For Preemption Of Type Of Graft-Versus-Host Disease

* KAMADA ANNOUNCES COLLABORATION WITH A CONSORTIUM OF PROMINENT HOSPITALS LED BY THE MOUNT SINAI HOSPITAL TO EVALUATE ITS ALPHA-1 ANTITRYPSIN PRODUCT FOR PREEMPTION OF STEROID REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE

Jan 04 2018

BRIEF-Kamada announces new supply agreement with international organization for KamRAB

* Kamada announces new supply agreement with international organization for KamRAB for post-exposure prophylaxis against rabies infection

Nov 21 2017

BRIEF-Kamada and ‍Chiesi Farmaceutici terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

* Kamada Ltd - Co, ‍chiesi Farmaceutici S.P.A. mutually agree to terminate European distribution agreement for inhaled alpha-1 antitrypsin therapy

Nov 20 2017

Earnings vs. Estimates

No consensus analysis data available.